cerium has been researched along with Hypertension, Pulmonary in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdelmonsif, DA; ElAchy, SN; Hassaan, PS; Nassar, SZ | 1 |
| Arvapalli, R; Blough, ER; Dornon, L; Hamlekhan, A; He, K; Kolli, MB; Ma, JY; Manne, NDPK; Nalabotu, SK; Nandyala, G; Para, R; Rice, KM; Shokuhfar, T; Wehner, PS | 1 |
2 other study(ies) available for cerium and Hypertension, Pulmonary
| Article | Year |
|---|---|
Cardioprotective effect of cerium oxide nanoparticles in monocrotaline rat model of pulmonary hypertension: A possible implication of endothelin-1.
Topics: Animals; Apoptosis; Cardiotonic Agents; Cerium; Electrocardiography; Endothelin-1; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Male; Monocrotaline; Nanoparticles; Nucleosides; Organ Size; Oxidative Stress; Poisons; Rats; Rats, Sprague-Dawley; Respiratory Function Tests; Triazoles | 2018 |
Cerium oxide nanoparticles attenuate monocrotaline induced right ventricular hypertrophy following pulmonary arterial hypertension.
Topics: Animals; Antioxidants; Cerium; Heart Ventricles; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Male; Monocrotaline; Nanoparticles; Rats; Rats, Sprague-Dawley | 2014 |